drugset
drugset / Trial / NCT05039723

Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational

NCT05039723 ↗

Phase 4 Completed 22 enrolled Main Line Center for Laser Surgery Merz North America, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the improvement in signs of photoaging and subject satisfaction after combination, global facial and/or neck treatment with IncobotulinumA (Xeomin), HA (Belotero) and/or calcium hydroxyapatite (Radiesse+, Radiesse Classic). All products will be used on-label FDA-cleared indications.

Timeline

Start
2021-09-01
Primary completion
2022-03-01
Completion
2022-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Hyaluronic Acid Other / unclassified — —
Subject IncobotulinumA Unknown — —
Subject calcium hydroxylapatite Unknown — —

Indications

No indication recorded.